Categories: The Charlton Centre

A new program for osteoarthritis: GLA:D®

The GLA:D program is an education and exercise program developed by researchers in Denmark for individuals with hip or knee osteoarthritis symptoms. Research from the GLA:D program in Denmark has shown a reduction in progression of symptoms by 27%. Other outcomes include a reduction in pain intensity, reduced use of joint related pain killers, and fewer individuals on sick leave. Program participants also reported high levels of satisfaction with the program and increased levels of physical activity 12 months after starting the program. (Information from gladcanada.ca)

There are now several centres within Ontario that offer the GLA:D program. Visit their website to find the centre closest to you.  I have spoken with physiotherapists involved with GLA:D and am very impressed with the results the program provides.


Carolyn Whiskin is the Pharmacy Manager for Charlton Health.  Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.

admin

Recent Posts

Bimzelx Now Approved for Hidradenitis Suppurativa (HS)

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition that can be very painful and…

4 days ago

Happy Holidays from Charlton Health

As the year comes to a close, we wish you a joyful holiday season filled…

3 weeks ago

Winrevair: A New Treatment Option for Pulmonary Arterial Hypertension (PAH)

Pulmonary arterial hypertension occurs when there is increased pressure in the small blood vessels that…

1 month ago

New Biologic Treatment for PMR (Polymyalgia Rheumatica)

Polymyalgia rheumatica (PMR) is an inflammatory condition that causes widespread joint and muscle pain along…

2 months ago

Expanded Protection: RSV Vaccine Now Approved for More Adults

Respiratory Syncytial Virus (RSV) is a common virus that can cause serious lung infections, particularly in…

2 months ago

Rinvoq: A New Oral Option for Giant Cell Arteritis

Health Canada has recently approved Rinvoq (upadacitinib) for adults living with Giant Cell Arteritis (GCA). Rinvoq…

3 months ago